DE69331051T2 - Neue verwendung von omega-3-fettsäuren - Google Patents

Neue verwendung von omega-3-fettsäuren

Info

Publication number
DE69331051T2
DE69331051T2 DE69331051T DE69331051T DE69331051T2 DE 69331051 T2 DE69331051 T2 DE 69331051T2 DE 69331051 T DE69331051 T DE 69331051T DE 69331051 T DE69331051 T DE 69331051T DE 69331051 T2 DE69331051 T2 DE 69331051T2
Authority
DE
Germany
Prior art keywords
omega
pct
preparations
fatty acids
dic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69331051T
Other languages
English (en)
Other versions
DE69331051D1 (de
Inventor
Nils Egberg
Carin Larsson-Backstroem
Jan Jakobsson
Rolf Lundh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi AB
Original Assignee
Fresenius Kabi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi AB filed Critical Fresenius Kabi AB
Application granted granted Critical
Publication of DE69331051D1 publication Critical patent/DE69331051D1/de
Publication of DE69331051T2 publication Critical patent/DE69331051T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69331051T 1992-02-24 1993-02-23 Neue verwendung von omega-3-fettsäuren Expired - Lifetime DE69331051T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids
PCT/SE1993/000146 WO1993016691A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids

Publications (2)

Publication Number Publication Date
DE69331051D1 DE69331051D1 (de) 2001-12-06
DE69331051T2 true DE69331051T2 (de) 2002-06-13

Family

ID=20385410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331051T Expired - Lifetime DE69331051T2 (de) 1992-02-24 1993-02-23 Neue verwendung von omega-3-fettsäuren

Country Status (13)

Country Link
US (2) US5747533A (de)
EP (1) EP0627918B1 (de)
JP (1) JP3559280B2 (de)
AT (1) ATE207744T1 (de)
AU (1) AU671438B2 (de)
CA (1) CA2117535A1 (de)
DE (1) DE69331051T2 (de)
DK (1) DK0627918T3 (de)
ES (1) ES2162620T3 (de)
NO (1) NO309704B1 (de)
SE (1) SE9200541D0 (de)
SG (1) SG46238A1 (de)
WO (1) WO1993016691A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
US6313167B1 (en) * 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
CA2227706C (en) * 1998-01-21 2010-08-03 Patrick Pageat Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
US6054481A (en) 1998-01-21 2000-04-25 Fideline Pig appeasing pheromones for enhancing weight gain in a mammal
BR9917806B1 (pt) * 1998-01-21 2013-06-18 composiÇço de feromona para tratamento de estresse ou ansiedade em mamÍferos, e soluÇço.
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
FR2804023B1 (fr) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr Complement nutritionnel a base d'huile de pepins de cassis
JP2004527501A (ja) * 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
WO2006036967A1 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Solubilizing a drug for use in a coating
WO2007011385A2 (en) 2004-09-28 2007-01-25 Atrium Medical Corporation Heat cured gel and method of making
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
EP2083875B1 (de) 2006-11-06 2013-03-27 Atrium Medical Corporation Beschichtetes chirurgisches netz
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
WO2009009040A2 (en) * 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2211881A4 (de) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine Zusammensetzungen und verfahren zur prävention und behandlung von krankheiten von säugetieren
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) * 2007-11-30 2010-12-23 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
EP2593141B1 (de) 2010-07-16 2018-07-04 Atrium Medical Corporation Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3785667T2 (de) * 1986-09-17 1994-07-21 Clintec Nutrition Co Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen.
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Also Published As

Publication number Publication date
ES2162620T3 (es) 2002-01-01
WO1993016691A1 (en) 1993-09-02
DE69331051D1 (de) 2001-12-06
SG46238A1 (en) 1998-02-20
NO943102D0 (no) 1994-08-23
JP3559280B2 (ja) 2004-08-25
NO943102L (no) 1994-10-21
EP0627918B1 (de) 2001-10-31
ATE207744T1 (de) 2001-11-15
AU671438B2 (en) 1996-08-29
SE9200541D0 (sv) 1992-02-24
US5731346A (en) 1998-03-24
EP0627918A1 (de) 1994-12-14
NO309704B1 (no) 2001-03-19
US5747533A (en) 1998-05-05
CA2117535A1 (en) 1993-09-02
JPH07507766A (ja) 1995-08-31
DK0627918T3 (da) 2002-01-14
AU3652993A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
DE69331051T2 (de) Neue verwendung von omega-3-fettsäuren
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
ES2174833T3 (es) Fosfolipidos.
KR910004199A (ko) 수성 이고제형 제약 조성물
PT1229800E (pt) Emulsao contendo agua e oleo
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE50012804D1 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
DE69122170T2 (de) Verwendung von Magnesium-pyridoxal-5'-phosphat-Glutaminat zur Verhinderung von Krankheiten verursacht durch Gefässläsionen
Brown et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs
ATE73996T1 (de) Verwendung lang- und mittelkettiger triglyzeride.
AU600502B2 (en) Body lubricating and cleansing fluid
SE8801710D0 (sv) New ophtalmological composition of matter
DE3878812T2 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
DE69005459D1 (de) Anreicherungsverfahren der fette an polyungesättigten fettsäuren und phospholipiden und anwendung dieser angereicherten fette.
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
DK0746551T3 (da) Optisk rene 4-aryl-2-hydroxytetronsyrer
FR2603587A1 (fr) Derives de la 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonine (ou -1,4-benzoxazonine), procede pour leur preparation, medicaments les contenant et composes intermediaires
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
ES2074264T3 (es) Esteres de aminoacidos de la hidroquinona, su procedimiento de preparacion y composiciones farmaceuticas o cosmeticas que los contienen.
NO975155L (no) Anvendelse av forskolin eller ekstakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet
Khan Dido and the Sword of Aeneas
JPS57209218A (en) Antithrombotic
KR940011003A (ko) 우르솔린산을 함유하는 혈관형성 억제제 조성물
ATE99692T1 (de) Optisch aktive rhodiumkomplexe von 3,4bis(diarylphosphino)-pyrrolidinen und ihre verwendung zur herstellung von phosphinothricin durch asymmetrische hydrierung.
Desmond " Huckleberry Finn" and the Failure of Anamnesis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 627918

Country of ref document: EP